Disc Medicine, Inc. 8-K

What Happened

• On January 12, 2026, Disc Medicine, Inc. filed a Form 8‑K and issued a press release announcing a preliminary, unaudited balance of approximately $791 million in cash, cash equivalents and marketable securities as of December 31, 2025.
• The company also disclosed recent achievements, its 2026 business objectives, and provided presentation materials for its participation in the 44th Annual J.P. Morgan Healthcare Conference (including an investor presentation scheduled for January 14, 2026).
• The $791M figure is preliminary, subject to completion of year‑end close procedures, and has not been audited or reviewed by the company’s independent registered public accounting firm.

Key Details

• Preliminary liquidity: approximately $791 million in cash, cash equivalents and marketable securities as of 12/31/2025.
• Filing and press release date: January 12, 2026.
• Audit status: amount is unaudited and subject to change upon financial statement closing; independent auditor has not provided assurance.
• Event: Company will present at the 44th Annual J.P. Morgan Healthcare Conference; presentation materials were filed with the 8‑K.

Why It Matters

• A reported cash and marketable securities balance is a key liquidity indicator for investors—especially for a clinical‑stage biotech—because it relates to the company’s ability to fund operations and development programs.
• Because the amount is preliminary and unaudited, investors should wait for the company’s completed year‑end financial statements (Form 10‑K) for a definitive view of financial position and results.
• The J.P. Morgan presentation materials may provide additional context on milestones and plans for 2026; investors can review those materials and the forthcoming Form 10‑K for fuller detail.